CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 25 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-09-17 | Melian Agustin Chief Medical Officer | Sale | −2,950 | $24.01 | $71K | 475,968 |
| 2021-09-15 | Melian Agustin Chief Medical Officer | Sale | −800 | $24.03 | $19K | 478,918 |
| 2021-09-02 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −513 | $19.86 | $10K | 441,095 |
| 2021-08-17 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −15,205 | $17.82 | $271K | 441,608 |
| 2021-07-02 | Melian Agustin Chief Medical Officer | Sale | −18,586 | $19.99 | $372K | 479,718 |
| 2021-06-03 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −508 | $22.87 | $12K | 456,813 |
| 2021-05-25 | GADICKE ANSBERT Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2021-05-25 | Hallal David Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2021-05-25 | Brenner Malcolm Director | Gift | −818,663 | 0 | ||
| 2021-05-25 | Brenner Malcolm Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2021-05-25 | Wilson John Robert Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2021-05-25 | Bornstein Jeffrey S Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2021-05-25 | Vera Juan Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2021-05-25 | Jovan-Embiricos Morana Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2021-05-18 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −15,201 | $22.80 | $347K | 457,321 |
| 2021-05-17 | Brainard Diana Chief Executive Officer | Grant or award | +30,000 | 36,300 | ||
| 2021-05-17 | Brainard Diana Chief Executive Officer | Grant or award | +170,000 | 206,300 | ||
| 2021-05-17 | Brainard Diana Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2021-05-10 | Leen Ann M. Chief Scientific Officer | Sale | −150,000 | $22.75 | $3.4M | 2,309,142 |
| 2021-04-05 | Melian Agustin Chief Medical Officer | Sale | −18,212 | $23.89 | $435K | 498,304 |
Page 18 of 27 · 527 trades